Literature DB >> 29272392

Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.

Stéphane Hua1, Selena Vigano1, Samantha Tse1, Ouyang Zhengyu1, Sean Harrington1, Jordi Negron1, Pilar Garcia-Broncano1,2, Giulia Marchetti3, Miguel Genebat4, Manuel Leal4, Salvador Resino2, Ezequiel Ruiz-Mateos4,5, Mathias Lichterfeld1,6, Xu G Yu1,6.   

Abstract

Background: Interferon alpha (IFN-α) can potently reduce human immunodeficiency virus type 1 (HIV-1) replication in tissue culture and animal models, but may also modulate residual viral reservoirs that persist despite suppressive antiretroviral combination therapy. However, mechanisms leading to viral reservoir reduction during IFN-α treatment are unclear.
Methods: We analyzed HIV-1 gag DNA levels in CD4 T cells by digital droplet polymerase chain reaction and CD8 T-cell and natural killer (NK) cell phenotypes by flow cytometry in a cohort of antiretroviral therapy-treated HIV-1/hepatitis C virus-coinfected patients (n = 67) undergoing treatment for hepatitis C infection with pegylated IFN-α and ribavirin for an average of 11 months.
Results: We observed that IFN-α treatment induced a significant decrease in CD4 T-cell counts (P < .0001), in CD4 T-cell-associated HIV-1 DNA copies (P = .002) and in HIV-1 DNA copies per microliter of blood (P < .0001) in our study patients. Notably, HIV-1 DNA levels were unrelated to HIV-1-specific CD8 T-cell responses. In contrast, proportions of total NK cells, CD56brightCD16- NK cells, and CD56brightCD16+ NK cells were significantly correlated with reduced levels of CD4 T-cell-associated HIV-1 DNA during IFN-α treatment, especially when coexpressing the activation markers NKG2D and NKp30. Conclusions: These data suggest that the reduction of viral reservoir cells during treatment with IFN-α is primarily attributable to antiviral activities of NK cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29272392      PMCID: PMC5982807          DOI: 10.1093/cid/cix1111

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

1.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

2.  A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.

Authors:  Adam M Spivak; Adriana Andrade; Evelyn Eisele; Rebecca Hoh; Peter Bacchetti; Namandjé N Bumpus; Fatemeh Emad; Robert Buckheit; Elinore F McCance-Katz; Jun Lai; Margene Kennedy; Geetanjali Chander; Robert F Siliciano; Janet D Siliciano; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2013-12-12       Impact factor: 9.079

3.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard
Journal:  Lancet HIV       Date:  2014-09-15       Impact factor: 12.767

4.  Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection.

Authors:  Hiroshi Takata; Supranee Buranapraditkun; Cari Kessing; James L K Fletcher; Roshell Muir; Virginie Tardif; Pearline Cartwright; Claire Vandergeeten; Wendy Bakeman; Carmen N Nichols; Suteeraporn Pinyakorn; Pokrath Hansasuta; Eugene Kroon; Thep Chalermchai; Robert O'Connell; Jerome Kim; Nittaya Phanuphak; Merlin L Robb; Nelson L Michael; Nicolas Chomont; Elias K Haddad; Jintanat Ananworanich; Lydie Trautmann
Journal:  Sci Transl Med       Date:  2017-02-15       Impact factor: 17.956

5.  Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming.

Authors:  Agnes Le Bon; Vanessa Durand; Elisabeth Kamphuis; Clare Thompson; Silvia Bulfone-Paus; Cornelia Rossmann; Ulrich Kalinke; David F Tough
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

6.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.

Authors:  Béatrice Jacquelin; Véronique Mayau; Brice Targat; Anne-Sophie Liovat; Désirée Kunkel; Gaël Petitjean; Marie-Agnès Dillies; Pierre Roques; Cécile Butor; Guido Silvestri; Luis D Giavedoni; Pierre Lebon; Françoise Barré-Sinoussi; Arndt Benecke; Michaela C Müller-Trutwin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

7.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

8.  HIV-1 DNA predicts disease progression and post-treatment virological control.

Authors:  James P Williams; Jacob Hurst; Wolfgang Stöhr; Nicola Robinson; Helen Brown; Martin Fisher; Sabine Kinloch; David Cooper; Mauro Schechter; Giuseppe Tambussi; Sarah Fidler; Mary Carrington; Abdel Babiker; Jonathan Weber; Kersten K Koelsch; Anthony D Kelleher; Rodney E Phillips; John Frater
Journal:  Elife       Date:  2014-09-12       Impact factor: 8.140

9.  Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.

Authors:  Alison L Hill; Daniel I S Rosenbloom; Edward Goldstein; Emily Hanhauser; Daniel R Kuritzkes; Robert F Siliciano; Timothy J Henrich
Journal:  PLoS Pathog       Date:  2016-04-27       Impact factor: 6.823

10.  Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth.

Authors:  Maja Kiselinova; Ward De Spiegelaere; Maria Jose Buzon; Eva Malatinkova; Mathias Lichterfeld; Linos Vandekerckhove
Journal:  PLoS Pathog       Date:  2016-03-03       Impact factor: 6.823

View more
  19 in total

1.  Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.

Authors:  Abena K R Kwaa; Chloe A G Talana; Joel N Blankson
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 2.  HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters.

Authors:  Sho Sugawara; David L Thomas; Ashwin Balagopal
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-15       Impact factor: 2.205

Review 3.  Type I Interferons in NeuroHIV.

Authors:  Victoria E Thaney; Marcus Kaul
Journal:  Viral Immunol       Date:  2018-09-27       Impact factor: 2.257

4.  NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Andrew V Kossenkov; Noor Dawany; Knashawn H Morales; Matthew Fair; Brian N Ross; Kenneth Lynn; Agnieszka Mackiewicz; Karam Mounzer; Pablo Tebas; Jeffrey M Jacobson; Jay R Kostman; Louise Showe; Luis J Montaner
Journal:  J Immunol       Date:  2019-06-28       Impact factor: 5.422

Review 5.  Engaging innate immunity in HIV-1 cure strategies.

Authors:  Nathan L Board; Milica Moskovljevic; Fengting Wu; Robert F Siliciano; Janet D Siliciano
Journal:  Nat Rev Immunol       Date:  2021-11-25       Impact factor: 108.555

6.  Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Amélie Pagliuzza; Mohamed Abdel-Mohsen; Brian N Ross; Matthew Fair; Bonnie J Howell; Daria J Hazuda; Nicolas Chomont; Qingsheng Li; Karam Mounzer; Jay R Kostman; Pablo Tebas; Luis J Montaner
Journal:  AIDS Res Hum Retroviruses       Date:  2021-01-29       Impact factor: 1.723

Review 7.  Interferon-α Subtypes As an Adjunct Therapeutic Approach for Human Immunodeficiency Virus Functional Cure.

Authors:  Jeffy George; Joseph J Mattapallil
Journal:  Front Immunol       Date:  2018-02-22       Impact factor: 7.561

8.  Propofol Promotes Activity and Tumor-Killing Ability of Natural Killer Cells in Peripheral Blood of Patients with Colon Cancer.

Authors:  Dongshui Liu; Xiaoshan Sun; Yue Du; Minmin Kong
Journal:  Med Sci Monit       Date:  2018-09-03

Review 9.  Targeting the Latent Reservoir for HIV-1.

Authors:  Srona Sengupta; Robert F Siliciano
Journal:  Immunity       Date:  2018-05-15       Impact factor: 31.745

Review 10.  Lymph Node Cellular and Viral Dynamics in Natural Hosts and Impact for HIV Cure Strategies.

Authors:  Nicolas Huot; Steven E Bosinger; Mirko Paiardini; R Keith Reeves; Michaela Müller-Trutwin
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.